Načítá se...
IL-33 in Tumor Immunity: Nothing to Sneeze At
Although immunotherapy has been at the forefront of cancer therapy for the last several years, better clinical responses are still desired. Interleukin-33 is perhaps one of the most overlooked antitumor cytokines. Its ability to promote type 1 immune responses, winch control tumor growth in preclini...
Uloženo v:
| Vydáno v: | Crit Rev Immunol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7087446/ https://ncbi.nlm.nih.gov/pubmed/31002600 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1615/CritRevImmunol.2018026335 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|